ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

About this episode

The episode discusses key wins and developments from the ASCO annual meeting and recent pharmaceutical partnerships, including updates on various oncology treatments and upcoming events.

At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics’ Chinese partner Akeso stole the show . For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso’s clinical trial in China will hold up in a global population . Immuneering , BMS/BioNTech , Merck , Pfizer and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival for its mRNA-based personalized melanoma vaccine. Outside of ASCO, the past week saw Pfizer strike an unusual pact with China’s Innovent Biologics as it seeks to bolster its oncology pipeline . Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach to working with Chinese companies. We’ll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall. Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn with former regulator…

People in this episode

Host: BioSpace

Topics covered

• oncology
• clinical trials
• pharmaceutical partnerships
• FDA approvals
• diabetes

Keywords

• ASCO
• oncology
• clinical trials
• Eli Lilly
• FDA
• diabetes
• RevMed
• Akeso
• Moderna
• NurOwn

Mentioned in this episode

Organizations: American Society of Clinical Oncology, Revolution Medicines, Summit Therapeutics, Akeso, Immuneering, BMS, BioNTech, Merck, Pfizer, Moderna

Products: NurOwn

Places: Chicago, China, New Orleans

More episodes of BioSpace

• Portugal, Spain and the new biotech frontier · June 10, 2026 · 21 min
• Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence · June 10, 2026 · 25 min
• Rethinking hair loss treatment · June 3, 2026 · 22 min
• France’s biotech ecosystem: science, capital and scale · May 28, 2026 · 21 min
• Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds · May 27, 2026 · 25 min
• Inside Germany’s biotech capital infrastructure and innovation engine · May 21, 2026 · 23 min